Clinical Trials for Uterine Cancer

An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Biomarker-selected adults with recurrent ovarian (including fallopian tube/primary peritoneal) or endometrial cancer receive abemaciclib, a CDK4/6 inhibitor targeting cyclin D–CDK4/6–RB signaling; ovarian cases require CDK4/6 pathway activation, and endometrioid endometrial tumors must be HR-positive without CCNE amplification or RB loss. Hormone receptor–positive tumors may also receive an aromatase inhibitor (anastrozole or letrozole).

ClinicalTrials.gov ID: NCT04469764

A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adult women with recurrent gynecologic carcinosarcoma after at least one prior systemic regimen (ECOG 0–2), this single-arm study gives cabozantinib (oral MET/VEGFR2/AXL multikinase inhibitor) plus dostarlimab (anti–PD-1) with maintenance dosing. Key exclusions include prior cabozantinib, unstable CNS disease, significant bleeding/GI risk, uncontrolled CV/HTN, active autoimmune disease requiring systemic therapy, and contraindicated anticoagulation.

ClinicalTrials.gov ID: NCT05559879

A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or recurrent endometrioid endometrial carcinoma (ECOG 0–1) with measurable disease and ≤1 prior systemic chemotherapy in the metastatic/advanced setting receive nab-sirolimus IV (albumin-bound mTORC1 inhibitor) on Days 1 and 8 of 21-day cycles plus daily letrozole. Excludes prior mTOR inhibitor exposure and active brain metastases; aims to assess response by RECIST with treatment continued until progression or intolerance.

ClinicalTrials.gov ID: NCT05997017

A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic CLDN6-positive solid tumors (e.g., ovarian, endometrial, testicular, subsets of NSCLC) receive TORL-1-23 monotherapy, an anti-CLDN6 antibody–drug conjugate delivering MMAE via a cleavable linker, in dose-escalation with tumor-specific expansions. Eligible patients have ECOG 0–1 and adequate organ function; key exclusions include active/symptomatic CNS disease and uncontrolled comorbidities.

ClinicalTrials.gov ID: NCT05103683

Phase 2, Randomized, Trial of Maintenance Letrozole/Abemaciclib vs Pembrolizumab After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wild-type Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with ER-positive (≥1%), MMR-proficient, TP53 wild-type advanced or recurrent endometrioid endometrial cancer (or carcinosarcoma with endometrioid component) who have completed induction carboplatin/paclitaxel plus pembrolizumab are randomized to maintenance abemaciclib (CDK4/6 inhibitor) plus letrozole (aromatase inhibitor) versus pembrolizumab monotherapy. Designed to test whether endocrine/CDK4/6 maintenance improves PFS versus standard PD-1 blockade maintenance in this biomarker-defined, non–TMB-high population.

ClinicalTrials.gov ID: NCT06366347

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with TP53 wild-type advanced or recurrent endometrial carcinoma (endometrioid, serous, undifferentiated, or carcinosarcoma) who achieved CR/PR after at least 12 weeks of first-line platinum therapy are randomized to maintenance selinexor vs placebo. Selinexor is an oral exportin 1 (XPO1) inhibitor that promotes nuclear retention/reactivation of tumor suppressors; treatment is 60 mg once weekly on a 28-day cycle.

ClinicalTrials.gov ID: NCT05611931

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16×CD3 Bispecific Antibody, Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent epithelial ovarian, primary peritoneal, fallopian tube, or other MUC16-positive cancers (including MUC16+ endometrial) after prior platinum therapy and without standard options; a randomized cohort targets platinum‑resistant ovarian cancer after 2–4 prior lines. Investigational therapy is ubamatamab, a MUC16×CD3 T cell–engaging bispecific antibody, given IV as monotherapy or combined with the anti–PD‑1 antibody cemiplimab.

ClinicalTrials.gov ID: NCT03564340

Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with PRAME-expressing, recurrent/refractory solid tumors (HLA‑A*02:01+, ECOG 0–1) receive autologous PRAME‑specific TCR‑T therapy (IMA203 or IMA203CD8) after cyclophosphamide/fludarabine lymphodepletion, with low‑dose IL‑2 support and an arm combining IMA203 with nivolumab. IMA203 targets a PRAME peptide via engineered TCR, while IMA203CD8 co‑expresses CD8αβ to enable CD4/CD8 T‑cell tumor killing; nivolumab (PD‑1 inhibitor) is tested for potential synergy.

ClinicalTrials.gov ID: NCT03686124

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent/persistent RAS-pathway–mutant ovarian, fallopian tube, primary peritoneal, or endometrial cancers (KRAS/NRAS/HRAS/BRAF/MEK1/MEK2 activating or NF1 loss), measurable and biopsiable, are randomized to selumetinib (MEK1/2 inhibitor) plus olaparib (PARP inhibitor) versus selumetinib alone; ovarian patients must be platinum-ineligible and endometrial patients should have received or been offered immunotherapy (± lenvatinib). No prior MEK inhibitors or progression on PARP allowed; crossover to the combination is permitted at progression from selumetinib monotherapy.

ClinicalTrials.gov ID: NCT05554328

A Phase 2A, Prospective, Open Label, Single Institution Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adult women with recurrent/metastatic cervical cancer (squamous, adeno, or adenosquamous), ECOG 0–1, up to two prior systemic lines allowed, including prior PD-1/PD-L1 and antiangiogenic therapy, receive pembrolizumab (PD-1 inhibitor) plus lenvatinib (VEGFR/FGFR/PDGFR/RET/KIT multikinase antiangiogenic) until progression or 2 years, with an option for retreatment. Excludes uncontrolled CNS disease and conditions that raise antiangiogenic risk (e.g., significant cardiovascular disease, proteinuria, GI fistula).

ClinicalTrials.gov ID: NCT06266338